JP2019516352A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019516352A5 JP2019516352A5 JP2018551409A JP2018551409A JP2019516352A5 JP 2019516352 A5 JP2019516352 A5 JP 2019516352A5 JP 2018551409 A JP2018551409 A JP 2018551409A JP 2018551409 A JP2018551409 A JP 2018551409A JP 2019516352 A5 JP2019516352 A5 JP 2019516352A5
- Authority
- JP
- Japan
- Prior art keywords
- clone
- seq
- amino acid
- receptor
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 25
- 125000003275 alpha amino acid group Chemical group 0.000 claims 20
- 230000000139 costimulatory effect Effects 0.000 claims 16
- -1 OX-40 Proteins 0.000 claims 14
- 108091008874 T cell receptors Proteins 0.000 claims 13
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 13
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 12
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 12
- 239000002157 polynucleotide Substances 0.000 claims 12
- 102000040430 polynucleotide Human genes 0.000 claims 12
- 108091033319 polynucleotide Proteins 0.000 claims 12
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims 11
- 125000000539 amino acid group Chemical group 0.000 claims 11
- 239000000427 antigen Substances 0.000 claims 11
- 102000036639 antigens Human genes 0.000 claims 11
- 108091007433 antigens Proteins 0.000 claims 11
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 10
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 claims 10
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 claims 10
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 claims 10
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 claims 10
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims 10
- 102100029215 Signaling lymphocytic activation molecule Human genes 0.000 claims 8
- 230000004913 activation Effects 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 210000002865 immune cell Anatomy 0.000 claims 7
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 claims 6
- 102100032816 Integrin alpha-6 Human genes 0.000 claims 6
- 102100025390 Integrin beta-2 Human genes 0.000 claims 6
- 108010074687 Signaling Lymphocytic Activation Molecule Family Member 1 Proteins 0.000 claims 6
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 claims 5
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 claims 5
- 210000001744 T-lymphocyte Anatomy 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 102100024263 CD160 antigen Human genes 0.000 claims 4
- 102100038077 CD226 antigen Human genes 0.000 claims 4
- 102100038078 CD276 antigen Human genes 0.000 claims 4
- 101000761938 Homo sapiens CD160 antigen Proteins 0.000 claims 4
- 101000884298 Homo sapiens CD226 antigen Proteins 0.000 claims 4
- 101001078158 Homo sapiens Integrin alpha-1 Proteins 0.000 claims 4
- 101000994375 Homo sapiens Integrin alpha-4 Proteins 0.000 claims 4
- 101000994365 Homo sapiens Integrin alpha-6 Proteins 0.000 claims 4
- 101001046687 Homo sapiens Integrin alpha-E Proteins 0.000 claims 4
- 101000971538 Homo sapiens Killer cell lectin-like receptor subfamily F member 1 Proteins 0.000 claims 4
- 101000873418 Homo sapiens P-selectin glycoprotein ligand 1 Proteins 0.000 claims 4
- 101000633786 Homo sapiens SLAM family member 6 Proteins 0.000 claims 4
- 101000633782 Homo sapiens SLAM family member 8 Proteins 0.000 claims 4
- 101000633780 Homo sapiens Signaling lymphocytic activation molecule Proteins 0.000 claims 4
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims 4
- 102100025323 Integrin alpha-1 Human genes 0.000 claims 4
- 102100032818 Integrin alpha-4 Human genes 0.000 claims 4
- 102100022341 Integrin alpha-E Human genes 0.000 claims 4
- 102100022339 Integrin alpha-L Human genes 0.000 claims 4
- 102100021458 Killer cell lectin-like receptor subfamily F member 1 Human genes 0.000 claims 4
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 claims 4
- 102100034925 P-selectin glycoprotein ligand 1 Human genes 0.000 claims 4
- 102000014128 RANK Ligand Human genes 0.000 claims 4
- 108010025832 RANK Ligand Proteins 0.000 claims 4
- 102100029197 SLAM family member 6 Human genes 0.000 claims 4
- 102100029214 SLAM family member 8 Human genes 0.000 claims 4
- 102100027744 Semaphorin-4D Human genes 0.000 claims 4
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 claims 4
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 108040006849 interleukin-2 receptor activity proteins Proteins 0.000 claims 4
- 239000003446 ligand Substances 0.000 claims 4
- 230000019491 signal transduction Effects 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 2
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 claims 2
- 101710145634 Antigen 1 Proteins 0.000 claims 2
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims 2
- 102100027205 B-cell antigen receptor complex-associated protein alpha chain Human genes 0.000 claims 2
- 101710095183 B-cell antigen receptor complex-associated protein alpha chain Proteins 0.000 claims 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 2
- 108010056102 CD100 antigen Proteins 0.000 claims 2
- 108010017009 CD11b Antigen Proteins 0.000 claims 2
- 102100027207 CD27 antigen Human genes 0.000 claims 2
- 101150013553 CD40 gene Proteins 0.000 claims 2
- 108010062802 CD66 antigens Proteins 0.000 claims 2
- 102100027217 CD82 antigen Human genes 0.000 claims 2
- 101710139831 CD82 antigen Proteins 0.000 claims 2
- 102100035793 CD83 antigen Human genes 0.000 claims 2
- 102100024533 Carcinoembryonic antigen-related cell adhesion molecule 1 Human genes 0.000 claims 2
- 102100025137 Early activation antigen CD69 Human genes 0.000 claims 2
- 101000585551 Equus caballus Pregnancy-associated glycoprotein Proteins 0.000 claims 2
- 102100022086 GRB2-related adapter protein 2 Human genes 0.000 claims 2
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 claims 2
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 claims 2
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 2
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims 2
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 claims 2
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 claims 2
- 101000900690 Homo sapiens GRB2-related adapter protein 2 Proteins 0.000 claims 2
- 101001035237 Homo sapiens Integrin alpha-D Proteins 0.000 claims 2
- 101001046683 Homo sapiens Integrin alpha-L Proteins 0.000 claims 2
- 101001046668 Homo sapiens Integrin alpha-X Proteins 0.000 claims 2
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 claims 2
- 101001047640 Homo sapiens Linker for activation of T-cells family member 1 Proteins 0.000 claims 2
- 101001090688 Homo sapiens Lymphocyte cytosolic protein 2 Proteins 0.000 claims 2
- 101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 claims 2
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims 2
- 101000589305 Homo sapiens Natural cytotoxicity triggering receptor 2 Proteins 0.000 claims 2
- 101001124867 Homo sapiens Peroxiredoxin-1 Proteins 0.000 claims 2
- 101000692259 Homo sapiens Phosphoprotein associated with glycosphingolipid-enriched microdomains 1 Proteins 0.000 claims 2
- 101000702132 Homo sapiens Protein spinster homolog 1 Proteins 0.000 claims 2
- 101000633778 Homo sapiens SLAM family member 5 Proteins 0.000 claims 2
- 101000633784 Homo sapiens SLAM family member 7 Proteins 0.000 claims 2
- 101000914496 Homo sapiens T-cell antigen CD7 Proteins 0.000 claims 2
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 claims 2
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 claims 2
- 101000795169 Homo sapiens Tumor necrosis factor receptor superfamily member 13C Proteins 0.000 claims 2
- 101000648507 Homo sapiens Tumor necrosis factor receptor superfamily member 14 Proteins 0.000 claims 2
- 101000679857 Homo sapiens Tumor necrosis factor receptor superfamily member 3 Proteins 0.000 claims 2
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims 2
- 102000009490 IgG Receptors Human genes 0.000 claims 2
- 108010073807 IgG Receptors Proteins 0.000 claims 2
- 108060003951 Immunoglobulin Proteins 0.000 claims 2
- 102100039904 Integrin alpha-D Human genes 0.000 claims 2
- 102100022338 Integrin alpha-M Human genes 0.000 claims 2
- 102100022297 Integrin alpha-X Human genes 0.000 claims 2
- 108010041100 Integrin alpha6 Proteins 0.000 claims 2
- 108010030465 Integrin alpha6beta1 Proteins 0.000 claims 2
- 102100025304 Integrin beta-1 Human genes 0.000 claims 2
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims 2
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 claims 2
- 241000713666 Lentivirus Species 0.000 claims 2
- 102100024032 Linker for activation of T-cells family member 1 Human genes 0.000 claims 2
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 claims 2
- 102100034709 Lymphocyte cytosolic protein 2 Human genes 0.000 claims 2
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 2
- 102000027581 NK cell receptors Human genes 0.000 claims 2
- 108091008877 NK cell receptors Proteins 0.000 claims 2
- 102100022683 NKG2-C type II integral membrane protein Human genes 0.000 claims 2
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims 2
- 108010004217 Natural Cytotoxicity Triggering Receptor 1 Proteins 0.000 claims 2
- 108010004222 Natural Cytotoxicity Triggering Receptor 3 Proteins 0.000 claims 2
- 102100032870 Natural cytotoxicity triggering receptor 1 Human genes 0.000 claims 2
- 102100032851 Natural cytotoxicity triggering receptor 2 Human genes 0.000 claims 2
- 102100032852 Natural cytotoxicity triggering receptor 3 Human genes 0.000 claims 2
- 102100038082 Natural killer cell receptor 2B4 Human genes 0.000 claims 2
- 101710141230 Natural killer cell receptor 2B4 Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 102100026066 Phosphoprotein associated with glycosphingolipid-enriched microdomains 1 Human genes 0.000 claims 2
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 claims 2
- 102100029216 SLAM family member 5 Human genes 0.000 claims 2
- 102100029198 SLAM family member 7 Human genes 0.000 claims 2
- 102000008115 Signaling Lymphocytic Activation Molecule Family Member 1 Human genes 0.000 claims 2
- 102100027208 T-cell antigen CD7 Human genes 0.000 claims 2
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 claims 2
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims 2
- 108010065158 Tumor Necrosis Factor Ligand Superfamily Member 14 Proteins 0.000 claims 2
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims 2
- 102100024586 Tumor necrosis factor ligand superfamily member 14 Human genes 0.000 claims 2
- 102100029690 Tumor necrosis factor receptor superfamily member 13C Human genes 0.000 claims 2
- 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 claims 2
- 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 claims 2
- 102100022156 Tumor necrosis factor receptor superfamily member 3 Human genes 0.000 claims 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 2
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims 2
- 101001038499 Yarrowia lipolytica (strain CLIB 122 / E 150) Lysine acetyltransferase Proteins 0.000 claims 2
- 108010082017 alpha chain interleukin-7 receptor Proteins 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 102000003675 cytokine receptors Human genes 0.000 claims 2
- 108010057085 cytokine receptors Proteins 0.000 claims 2
- 102000018358 immunoglobulin Human genes 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 102000006495 integrins Human genes 0.000 claims 2
- 108010044426 integrins Proteins 0.000 claims 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 2
- 210000002751 lymph Anatomy 0.000 claims 2
- 210000004698 lymphocyte Anatomy 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims 2
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 claims 2
- 241000701161 unidentified adenovirus Species 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000008720 Bone Marrow Neoplasms Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 208000015943 Coeliac disease Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 claims 1
- 208000036566 Erythroleukaemia Diseases 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000035490 Megakaryoblastic Acute Leukemia Diseases 0.000 claims 1
- 208000035489 Monocytic Acute Leukemia Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000037538 Myelomonocytic Juvenile Leukemia Diseases 0.000 claims 1
- 208000014767 Myeloproliferative disease Diseases 0.000 claims 1
- 206010034016 Paronychia Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 208000021841 acute erythroid leukemia Diseases 0.000 claims 1
- 208000013593 acute megakaryoblastic leukemia Diseases 0.000 claims 1
- 208000020700 acute megakaryocytic leukemia Diseases 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 230000000735 allogeneic effect Effects 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 201000006491 bone marrow cancer Diseases 0.000 claims 1
- 201000010902 chronic myelomonocytic leukemia Diseases 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 201000005992 juvenile myelomonocytic leukemia Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 208000008585 mastocytosis Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 239000013612 plasmid Substances 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022035975A JP7561155B2 (ja) | 2016-04-01 | 2022-03-09 | Ｆｌｔ３に対するキメラ受容体及びその使用方法 |
| JP2024070373A JP2024105337A (ja) | 2016-04-01 | 2024-04-24 | Ｆｌｔ３に対するキメラ受容体及びその使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662317219P | 2016-04-01 | 2016-04-01 | |
| US62/317,219 | 2016-04-01 | ||
| PCT/US2017/025613 WO2017173410A1 (en) | 2016-04-01 | 2017-03-31 | Chimeric receptors to flt3 and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022035975A Division JP7561155B2 (ja) | 2016-04-01 | 2022-03-09 | Ｆｌｔ３に対するキメラ受容体及びその使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019516352A JP2019516352A (ja) | 2019-06-20 |
| JP2019516352A5 true JP2019516352A5 (enExample) | 2020-05-07 |
Family
ID=58530714
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018551409A Pending JP2019516352A (ja) | 2016-04-01 | 2017-03-31 | Ｆｌｔ３に対するキメラ受容体及びその使用方法 |
| JP2022035975A Active JP7561155B2 (ja) | 2016-04-01 | 2022-03-09 | Ｆｌｔ３に対するキメラ受容体及びその使用方法 |
| JP2024070373A Pending JP2024105337A (ja) | 2016-04-01 | 2024-04-24 | Ｆｌｔ３に対するキメラ受容体及びその使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022035975A Active JP7561155B2 (ja) | 2016-04-01 | 2022-03-09 | Ｆｌｔ３に対するキメラ受容体及びその使用方法 |
| JP2024070373A Pending JP2024105337A (ja) | 2016-04-01 | 2024-04-24 | Ｆｌｔ３に対するキメラ受容体及びその使用方法 |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US20190183931A1 (enExample) |
| EP (1) | EP3436479A1 (enExample) |
| JP (3) | JP2019516352A (enExample) |
| KR (2) | KR102389096B1 (enExample) |
| CN (1) | CN109641956A (enExample) |
| AR (2) | AR109626A1 (enExample) |
| AU (3) | AU2017240801A1 (enExample) |
| CA (1) | CA3019655A1 (enExample) |
| CL (1) | CL2018002792A1 (enExample) |
| CO (1) | CO2018011804A2 (enExample) |
| CR (2) | CR20180518A (enExample) |
| EA (1) | EA201892193A1 (enExample) |
| IL (2) | IL296966A (enExample) |
| MA (1) | MA44507A (enExample) |
| MX (1) | MX2023013729A (enExample) |
| MY (2) | MY210545A (enExample) |
| NZ (1) | NZ746925A (enExample) |
| PE (2) | PE20241061A1 (enExample) |
| PH (1) | PH12018502118B1 (enExample) |
| SA (1) | SA518400154B1 (enExample) |
| SG (2) | SG10201911963VA (enExample) |
| TN (1) | TN2018000337A1 (enExample) |
| TW (2) | TWI776807B (enExample) |
| UA (1) | UA128326C2 (enExample) |
| WO (1) | WO2017173410A1 (enExample) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201116559D0 (en) | 2011-09-26 | 2011-11-09 | Univ Leuven Kath | Novel viral replication inhibitors |
| US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| CN105939767B (zh) | 2014-01-08 | 2018-04-06 | 弗洛设计声能学公司 | 具有双声电泳腔的声电泳装置 |
| US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
| US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
| JOP20160086B1 (ar) | 2015-05-08 | 2021-08-17 | 2 Katholieke Univ Leuven Ku Leuven Research And Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JO3633B1 (ar) | 2015-09-16 | 2020-08-27 | Katholieke Univ Leuven Ku Leuven Research & Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JOP20160198B1 (ar) | 2015-09-16 | 2022-03-14 | Janssen Pharmaceuticals Inc | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| HRP20210847T1 (hr) | 2016-03-31 | 2021-07-23 | Janssen Pharmaceuticals, Inc. | Supstituirani derivati indola kao inhibitori replikacije denga virusa |
| WO2017167953A1 (en) | 2016-03-31 | 2017-10-05 | Janssen Pharmaceuticals, Inc. | Substituted indoline derivatives as dengue viral replication inhibitors |
| EA201892200A1 (ru) | 2016-04-01 | 2019-03-29 | Янссен Фармасьютикалз, Инк. | Замещенные производные соединений индола в качестве ингибиторов репликации вирусов денге |
| SG10201912519VA (en) | 2016-04-01 | 2020-02-27 | Kite Pharma Inc | Chimeric receptors and methods of use thereof |
| KR102427334B1 (ko) * | 2016-04-01 | 2022-08-03 | 카이트 파마 인코포레이티드 | 키메라 항원 및 t 세포 수용체 및 사용 방법 |
| JOP20170069B1 (ar) | 2016-04-01 | 2021-08-17 | 1 Janssen Pharmaceuticals Inc | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| NZ746700A (en) | 2016-04-01 | 2023-04-28 | Kite Pharma Inc | Bcma binding molecules and methods of use thereof |
| US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
| EP3559038B1 (en) * | 2016-12-21 | 2022-12-14 | The United States of America as represented by The Secretary Department of Health and Human Services | Human monoclonal antibodies specific for flt3 and uses thereof |
| JOP20180026A1 (ar) | 2017-03-31 | 2019-01-30 | Univ Leuven Kath | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JOP20180025B1 (ar) | 2017-03-31 | 2021-08-17 | Janssen Pharmaceuticals Inc | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| CR20190531A (es) | 2017-05-22 | 2020-03-05 | Janssen Pharmaceuticals Inc | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue |
| CA3060583C (en) | 2017-05-22 | 2024-06-04 | Janssen Pharmaceuticals, Inc. | Substituted indoline derivatives as dengue viral replication inhibitors |
| PE20241587A1 (es) * | 2017-06-02 | 2024-08-01 | Pfizer | Receptores de antigenos quimericos que se dirigen a flt3 |
| CN118126157A (zh) | 2017-08-03 | 2024-06-04 | 美国安进公司 | 白介素-21突变蛋白和治疗方法 |
| US10640504B2 (en) | 2017-09-08 | 2020-05-05 | Amgen Inc. | Inhibitors of KRAS G12C and methods of using the same |
| MX2020007291A (es) | 2018-01-12 | 2020-09-10 | Amgen Inc | Anticuerpos anti-pd-1 y metodos de tratamiento. |
| AU2019240370B2 (en) * | 2018-03-23 | 2024-03-07 | Gavish-Galilee Bio Applications Ltd. | Genetically reprogrammed Tregs expressing membrane-bound IL-10 |
| CR20200539A (es) * | 2018-04-10 | 2021-07-01 | Kite Pharma Inc | Receptores quiméricos de dll3 y métodos para su uso |
| MX2020010808A (es) * | 2018-04-13 | 2021-03-02 | Sangamo Therapeutics France | Receptor de antigeno quimerico especifico para el receptor de interleucina-23. |
| EP3902836B1 (en) | 2018-12-18 | 2026-03-25 | Boehringer Ingelheim IO Canada Inc. | Flt3 agonist antibodies and uses thereof |
| CA3136618A1 (en) * | 2019-04-10 | 2020-10-15 | Elevatebio Technologies, Inc. | Flt3-specific chimeric antigen receptors and methods of using the same |
| JP7711945B2 (ja) | 2019-04-30 | 2025-07-23 | センティ バイオサイエンシズ インコーポレイテッド | キメラ受容体及びその使用方法 |
| PH12022551160A1 (en) | 2019-11-15 | 2023-09-25 | Janssen Pharmaceuticals Inc | Treatment and prevention of dengue disease |
| EP4076480A4 (en) * | 2019-12-16 | 2024-04-17 | Washington University | CHIMERIC ANTIGEN RECEPTOR DENDRITIC CELLS (CAR-DCS) AND METHODS OF MAKING AND USING THE SAME |
| JP2023522330A (ja) * | 2020-04-17 | 2023-05-30 | シティ・オブ・ホープ | Ｆｌｔ３陽性悪性腫瘍を処置するためのｆｌｔ３標的化キメラ抗原受容体改変細胞 |
| CN111808821B (zh) * | 2020-06-24 | 2022-06-14 | 南方医科大学珠江医院 | Flt3-nkg2d双靶点car-t的构建与制备 |
| JP2024500189A (ja) | 2020-12-21 | 2024-01-04 | アロジーン セラピューティクス，インコーポレイテッド | プロテアーゼ活性化ｃｄ４５ゲートｃａｒ |
| US12365873B2 (en) * | 2021-01-28 | 2025-07-22 | Allogene Therapeutics, Inc. | Methods for transducing immune cells |
| MX2023008809A (es) | 2021-01-29 | 2023-08-04 | Allogene Therapeutics Inc | ATENUACIÓN O INACTIVACIÓN DE UNO O MÁS DE TAP2, NLRC5, ß2M, TRAC, RFX5, RFXAP Y RFXANK PARA MITIGAR EL RECONOCIMIENTO DE CÉLULAS T DE PRODUCTOS CELULARES ALOGÉNICOS. |
| CN116410315A (zh) * | 2021-12-31 | 2023-07-11 | 博生吉医药科技(苏州)有限公司 | 一种新型靶向人flt3的嵌合抗原受体修饰的t细胞的构建及应用 |
| US20240042030A1 (en) | 2022-07-29 | 2024-02-08 | Allogene Therapeutics, Inc. | Engineered cells with reduced gene expression to mitigate immune cell recognition |
| KR20260105764A (ko) | 2023-10-30 | 2026-07-07 | 알로젠 테라퓨틱스 인코포레이티드 | 조작된 세포 |
| CN122381189A (zh) * | 2023-12-15 | 2026-07-14 | 博生吉安科细胞技术有限公司 | 一种识别flt3-car分子的单克隆抗体及其应用 |
| WO2026052582A1 (en) | 2024-09-04 | 2026-03-12 | Red Ridge Bio Ag | Biparatopic antibodies that specifically bind fms related receptor tyrosine kinase 3 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| EP0281604B1 (en) | 1986-09-02 | 1993-03-31 | Enzon Labs Inc. | Single polypeptide chain binding molecules |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US6319494B1 (en) | 1990-12-14 | 2001-11-20 | Cell Genesys, Inc. | Chimeric chains for receptor-associated signal transduction pathways |
| IL104570A0 (en) | 1992-03-18 | 1993-05-13 | Yeda Res & Dev | Chimeric genes and cells transformed therewith |
| US5830462A (en) | 1993-02-12 | 1998-11-03 | President & Fellows Of Harvard College | Regulated transcription of targeted genes and other biological events |
| US5869337A (en) | 1993-02-12 | 1999-02-09 | President And Fellows Of Harvard College | Regulated transcription of targeted genes and other biological events |
| US5834266A (en) | 1993-02-12 | 1998-11-10 | President & Fellows Of Harvard College | Regulated apoptosis |
| US20030036654A1 (en) | 1994-08-18 | 2003-02-20 | Holt Dennis A. | Synthetic multimerizing agents |
| US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| HK1052372A1 (zh) | 2000-02-24 | 2003-09-11 | Xcyte Therapies, Inc. | 细胞的同步刺激和富集 |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US7446190B2 (en) * | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| AU2006290433B2 (en) * | 2005-08-26 | 2012-06-07 | Roche Glycart Ag | Modified antigen binding molecules with altered cell signaling activity |
| US20100196336A1 (en) | 2006-05-23 | 2010-08-05 | Dongsu Park | Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods |
| ES2573642T3 (es) * | 2009-12-23 | 2016-06-09 | Synimmune Gmbh | Anticuerpos anti-FLT3 y métodos de usar los mismos |
| US9089520B2 (en) | 2010-05-21 | 2015-07-28 | Baylor College Of Medicine | Methods for inducing selective apoptosis |
| US9845362B2 (en) * | 2010-10-08 | 2017-12-19 | The University Of North Carolina At Charlotte | Compositions comprising chimeric antigen receptors, T cells comprising the same, and methods of using the same |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| US9024028B2 (en) | 2011-01-26 | 2015-05-05 | Ariad Pharmaceuticals, Inc. | Methods and compositions for the synthesis of multimerizing agents |
| WO2012129514A1 (en) | 2011-03-23 | 2012-09-27 | Fred Hutchinson Cancer Research Center | Method and compositions for cellular immunotherapy |
| CA2868121C (en) * | 2012-03-23 | 2021-06-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-mesothelin chimeric antigen receptors |
| IL305629A (en) | 2013-02-15 | 2023-11-01 | Univ California | Chimeric antigen receptor and methods of using it |
| CA2905352A1 (en) | 2013-03-14 | 2014-09-25 | Bellicum Pharmaceuticals, Inc. | Methods for controlling t cell proliferation |
| EP3027204B1 (en) | 2013-07-29 | 2022-01-05 | 2seventy bio, Inc. | Multipartite signaling proteins and uses thereof |
| WO2015090229A1 (en) | 2013-12-20 | 2015-06-25 | Novartis Ag | Regulatable chimeric antigen receptor |
| EP3104866A4 (en) | 2014-02-14 | 2017-08-02 | Bellicum Pharmaceuticals, Inc. | Methods for activating t cells using an inducible chimeric polypeptide |
| CN122399016A (zh) * | 2014-03-15 | 2026-07-17 | 诺华股份有限公司 | 使用嵌合抗原受体治疗癌症 |
| ES2743809T3 (es) * | 2014-07-31 | 2020-02-20 | Amgen Res Munich Gmbh | Constructos de anticuerpo monocatenarios biespecificos específicos de especies cruzadas optimizados |
| ES2738705T3 (es) * | 2014-09-19 | 2020-01-24 | Hope City | Linfocitos T de receptor de antígeno quimérico coestimulante que se dirigen a IL13R 2 |
| TWI829617B (zh) * | 2015-07-31 | 2024-01-21 | 德商安美基研究（慕尼黑）公司 | Ｆｌｔ３及ｃｄ３抗體構築體 |
| KR102427334B1 (ko) * | 2016-04-01 | 2022-08-03 | 카이트 파마 인코포레이티드 | 키메라 항원 및 t 세포 수용체 및 사용 방법 |
-
2017
- 2017-03-31 AU AU2017240801A patent/AU2017240801A1/en not_active Abandoned
- 2017-03-31 JP JP2018551409A patent/JP2019516352A/ja active Pending
- 2017-03-31 US US16/090,562 patent/US20190183931A1/en not_active Abandoned
- 2017-03-31 MA MA044507A patent/MA44507A/fr unknown
- 2017-03-31 EA EA201892193A patent/EA201892193A1/ru unknown
- 2017-03-31 PE PE2023001958A patent/PE20241061A1/es unknown
- 2017-03-31 EP EP17716764.0A patent/EP3436479A1/en active Pending
- 2017-03-31 MY MYPI2021006634A patent/MY210545A/en unknown
- 2017-03-31 CR CR20180518A patent/CR20180518A/es unknown
- 2017-03-31 SG SG10201911963VA patent/SG10201911963VA/en unknown
- 2017-03-31 IL IL296966A patent/IL296966A/en unknown
- 2017-03-31 UA UAA201810056A patent/UA128326C2/uk unknown
- 2017-03-31 WO PCT/US2017/025613 patent/WO2017173410A1/en not_active Ceased
- 2017-03-31 KR KR1020187031715A patent/KR102389096B1/ko active Active
- 2017-03-31 PH PH1/2018/502118A patent/PH12018502118B1/en unknown
- 2017-03-31 MY MYPI2018001669A patent/MY201207A/en unknown
- 2017-03-31 KR KR1020227012842A patent/KR102694879B1/ko active Active
- 2017-03-31 SG SG11201808622SA patent/SG11201808622SA/en unknown
- 2017-03-31 CR CR20240116A patent/CR20240116A/es unknown
- 2017-03-31 TN TNP/2018/000337A patent/TN2018000337A1/en unknown
- 2017-03-31 PE PE2018001940A patent/PE20190201A1/es unknown
- 2017-03-31 CA CA3019655A patent/CA3019655A1/en active Pending
- 2017-03-31 IL IL262061A patent/IL262061B2/en unknown
- 2017-03-31 CN CN201780033054.XA patent/CN109641956A/zh active Pending
- 2017-03-31 NZ NZ746925A patent/NZ746925A/en unknown
- 2017-04-03 AR ARP170100839A patent/AR109626A1/es unknown
- 2017-04-05 TW TW106111460A patent/TWI776807B/zh active
- 2017-04-05 TW TW111130070A patent/TW202313669A/zh unknown
-
2018
- 2018-10-01 MX MX2023013729A patent/MX2023013729A/es unknown
- 2018-10-01 CL CL2018002792A patent/CL2018002792A1/es unknown
- 2018-10-01 SA SA518400154A patent/SA518400154B1/ar unknown
- 2018-10-31 CO CONC2018/0011804A patent/CO2018011804A2/es unknown
-
2022
- 2022-01-10 AU AU2022200108A patent/AU2022200108C1/en active Active
- 2022-03-09 JP JP2022035975A patent/JP7561155B2/ja active Active
- 2022-05-23 US US17/751,586 patent/US20230124464A1/en active Pending
- 2022-10-14 AR ARP220102800A patent/AR127371A2/es unknown
-
2024
- 2024-04-24 JP JP2024070373A patent/JP2024105337A/ja active Pending
- 2024-12-18 AU AU2024278538A patent/AU2024278538A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20221348T1 (hr) | Kimerni receptori i postupci njihove uporabe | |
| JP2021520788A5 (enExample) | ||
| JP2022523781A5 (enExample) | ||
| JP2019515661A5 (enExample) | ||
| JP2021530233A5 (enExample) | ||
| JP2017522879A5 (enExample) | ||
| JP2021000103A5 (enExample) | ||
| RU2017105160A (ru) | Лечение рака с помощью химерного антигенного рецептора к cd33 | |
| RU2017105065A (ru) | Лечение злокачественного новообразования с использованием гуманизированного химерного антигенного рецептора против всма | |
| IL277398B2 (en) | Pd-l1 binding affimers, and uses related thereto | |
| RU2017105161A (ru) | Лечение рака с использованием химерного антигенного рецептора cll-1 | |
| JP2021518142A5 (enExample) | ||
| JP2019523301A5 (enExample) | ||
| JP2020513839A5 (enExample) | ||
| JP2019525771A5 (enExample) | ||
| JP2019516350A5 (enExample) | ||
| JP2018538339A5 (enExample) | ||
| CA3032054A1 (en) | Combination therapies of chimeric antigen receptors and pd-1 inhibitors | |
| JP2019513370A5 (enExample) | ||
| RU2017108903A (ru) | Химерный антигенный рецептор (car) против cd123 для использования в лечении злокачественных опухолей | |
| JP2024539506A5 (enExample) | ||
| RU2019128921A (ru) | Антитело к il-13ra2 и его применение | |
| JP2023518930A5 (enExample) | ||
| JP2024517027A5 (enExample) | ||
| JP2025513427A5 (enExample) |